Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T70071
|
||||
Former ID |
TTDR00416
|
||||
Target Name |
Endothelin converting enzyme
|
||||
Synonyms |
ECE
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Acute decompensated heart failure; Renal dysfunction [ICD9: 428, 428.0, 584, 585; ICD10: I50, N17-N19] | ||||
Brain injury [ICD10: S09.90] | |||||
Cardiovascular disorder [ICD10: I00-I99] | |||||
Hypertension [ICD9: 401; ICD10: I10-I16] | |||||
BioChemical Class |
Peptidase
|
||||
EC Number |
EC 3.4.24.71
|
||||
Drugs and Mode of Action | |||||
Drug(s) | SLV 306 | Drug Info | Phase 2 | Acute decompensated heart failure; Renal dysfunction | [521684], [541643] |
SLV-334 | Drug Info | Phase 2 | Brain injury | [531869] | |
SLV-338 | Drug Info | Phase 1 | Cardiovascular disorder | [531611] | |
SM-19712 | Drug Info | Terminated | Hypertension | [540736], [547354] | |
WS-75624B | Drug Info | Terminated | Cardiovascular disorder | [546199] | |
References | |||||
Ref 521684 | ClinicalTrials.gov (NCT00160225) Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension. U.S. National Institutes of Health. | ||||
Ref 531611 | Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15. | ||||
Ref 531869 | The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. | ||||
Ref 540736 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5272). | ||||
Ref 541643 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6506). | ||||
Ref 525891 | Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats. Jpn J Pharmacol. 2000 Sep;84(1):16-24. | ||||
Ref 531611 | Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15. | ||||
Ref 531869 | The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.